Firenze, Italy
Firenze, Italy

Time filter

Source Type

Azouaou N.,University of Science and Technology Houari Boumediene | Sadaoui Z.,University of Science and Technology Houari Boumediene | Djaafri A.,Central laboratory | Mokaddem H.,University of Science and Technology Houari Boumediene
Journal of Hazardous Materials | Year: 2010

Adsorption can be used as a cost effective and efficient technique for the removal of toxic heavy metals from wastewater. Waste materials with no further treatment such as coffee grounds from cafeterias may act as adsorbents for the removal of cadmium. Batch kinetic and equilibrium experiments were conducted to study the effects of contact time, adsorbent dose, initial pH, particle size, initial concentration of cadmium and temperature. Three adsorption isotherm models namely, Langmuir, Freundlich and Dubinin-Radushkevich were used to analyse the equilibrium data. The Langmuir isotherm which provided the best correlation for Cd2+ adsorption onto coffee grounds, shows that the adsorption was favourable and the adsorption capacity found was equal to 15.65mgg-1. Thermodynamic parameters were evaluated and the adsorption was exothermic. The equilibrium was achieved less than 120min. The adsorption kinetic data was fitted with first and second order kinetic models. Finally it was concluded that the cadmium adsorption kinetic onto coffee grounds was well fitted by second order kinetic model rather than first order model. The results suggest that coffee grounds have high possibility to be used as effective and economical adsorbent for Cd2+ removal. © 2010 Elsevier B.V.


News Article | February 23, 2017
Site: www.prnewswire.com

PALO ALTO, Calif. and LANCASTER, Pa., Feb. 23, 2017 /PRNewswire/ -- Science Exchange and Eurofins are excited to announce that Eurofins Central Laboratory is now a service provider listed on the Science Exchange marketplace for outsourced research services. This means that pharmaceutical a...


News Article | December 13, 2016
Site: marketersmedia.com

Wiseguyreports.Com Adds “Medical Automation -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database According to Stratistics MRC, the Global Medical Automation Technologies Market is estimated to be $52.67 billion in 2015 and is expected to reach $95.2 billion growing at a CAGR of 8.8%. The factors that are influencing the market growth include rising healthcare costs, investment by venture capitalists and the increase in use of point of care testing devices (glucose meters, digital blood pressure monitors, pregnancy test kits and HIV test kits). However the tax imposed by the U.S government on medical devices manufacturers and rigorous approval procedures to launch a product or services by companies is likely to hinder the market growth. North America is anticipated to hold the largest market share, followed by Europe. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. Increasing aged population, growing occurrence of CVDs, diabetes, and cancer, increased funding on healthcare and life sciences research are propelling the growth of the Asia-Pacific market. Furthermore, the rising need of automation in various other medical fields represents the growth opportunities for this market. Some of the major players in the Global Medical Automation Technologies Market include GE Healthcare, Philips Healthcare, Siemens Healthcare, Tecan Group Ltd., Stanley Black and Decker, Inc., Intuitive Surgical, Inc., CAE Ltd., Brainlab AG, Given Imaging Ltd. and Medtronic, Inc. Applications Covered: • Therapeutic Automation • Lab and Pharmacy Automation • Logistics and Training Automation • Diagnostics and Monitoring Automation End Users Covered: • Research Labs and Institutes • Hospitals and Diagnostic Centers • Pharmacies • Home/Ambulatory and Others Type of Technologies Covered: • Robotic and computer-assisted surgical equipment o Surgical robots o Surgical planners and simulators o Intelligent operating rooms and related equipment o Surgical navigation systems • Automated therapeutic (non-surgical) devices o Automated medication delivery systems o Automated defibrillators • Automated prescription fulfillment devices o Dispensing machines o Intravenous compounders o Packaging machines • Automated medical imaging and image analysis o Automated microscopy o Automated radiography and fluoroscopy o Automated skin cancer detection o Automated whole-breast ultrasound o Computer-aided detection o Endoscopic capsules • Automated laboratory testing and analysis o Point-of-care Testing Systems o Central Laboratory Systems • Automated healthcare logistics, resource and patient tracking o Hospital asset/patient/staff tracking systems o Automated hospital pickup and delivery • Automated health assessment and monitoring technologies o Wearable monitors o Telehealth kiosks o Automated home monitoring and telemetry o Automated eye examination devices o Automated drug testing Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements For more information, please visit https://www.wiseguyreports.com/sample-request/649650-medical-automation-global-market-outlook-2016-2022


News Article | December 5, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Medical Automation Technologies Market is estimated to be $52.67 billion in 2015 and is expected to reach $95.2 billion growing at a CAGR of 8.8%. The factors that are influencing the market growth include rising healthcare costs, investment by venture capitalists and the increase in use of point of care testing devices (glucose meters, digital blood pressure monitors, pregnancy test kits and HIV test kits). However the tax imposed by the U.S government on medical devices manufacturers and rigorous approval procedures to launch a product or services by companies is likely to hinder the market growth. North America is anticipated to hold the largest market share, followed by Europe. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. Increasing aged population, growing occurrence of CVDs, diabetes, and cancer, increased funding on healthcare and life sciences research are propelling the growth of the Asia-Pacific market. Furthermore, the rising need of automation in various other medical fields represents the growth opportunities for this market. Some of the major players in the Global Medical Automation Technologies Market include GE Healthcare, Philips Healthcare, Siemens Healthcare, Tecan Group Ltd., Stanley Black and Decker, Inc., Intuitive Surgical, Inc., CAE Ltd., Brainlab AG, Given Imaging Ltd. and Medtronic, Inc. Applications Covered: • Therapeutic Automation • Lab and Pharmacy Automation • Logistics and Training Automation • Diagnostics and Monitoring Automation End Users Covered: • Research Labs and Institutes • Hospitals and Diagnostic Centers • Pharmacies • Home/Ambulatory and Others Type of Technologies Covered: • Robotic and computer-assisted surgical equipment o Surgical robots o Surgical planners and simulators o Intelligent operating rooms and related equipment o Surgical navigation systems • Automated therapeutic (non-surgical) devices o Automated medication delivery systems o Automated defibrillators • Automated prescription fulfillment devices o Dispensing machines o Intravenous compounders o Packaging machines • Automated medical imaging and image analysis o Automated microscopy o Automated radiography and fluoroscopy o Automated skin cancer detection o Automated whole-breast ultrasound o Computer-aided detection o Endoscopic capsules • Automated laboratory testing and analysis o Point-of-care Testing Systems o Central Laboratory Systems • Automated healthcare logistics, resource and patient tracking o Hospital asset/patient/staff tracking systems o Automated hospital pickup and delivery • Automated health assessment and monitoring technologies o Wearable monitors o Telehealth kiosks o Automated home monitoring and telemetry o Automated eye examination devices o Automated drug testing Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific       • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


Ludwig Prof. H.,Center for Oncology | Muldur E.,Center for Oncology | Endler G.,Central Laboratory | Hubl W.,Central Laboratory
Annals of Oncology | Year: 2013

Background: Only limited data on the prevalence of iron deficiency (ID) and its correlation with clinical parameters are available in cancer. ID frequently contributes to the pathogenesis of anemia in patients with cancer and may lead to several symptoms such as impaired physical function, weakness and fatigue. Patients and methods: Parameters of iron status and clinical parameters were evaluated in 1528 patients with cancer who presented consecutively within a four-month period at our center. One thousand fifty-three patients had solid tumors and 475 hematological malignancies. Results: ID [transferrin saturation (TSAT) < 20%] was noted in 645 (42.6%) of the 1513 patients with TSAT tests available and 500 (33.0%) were anemic. ID rates were highest in pancreatic (63.2%), colorectal (51.9%) and lung cancers (50.7%). Of the 409 iron-deficient patients in whom serum ferritin levels were available additionally to TSAT, 335 (81.9%) presented with functional ID (FID) (TSAT < 20%, serum ferritin >30 ng/ml) and 74 (18.1%) with absolute ID. In patients with solid tumors, prevalence of ID correlated with cancer stage at diagnosis (P=0.001), disease status (P = 0.001) and ECOG performance status (P = 0.005). Conclusions: ID was frequently noted in cancer and was associated with advanced disease, close proximity to cancer therapy, and poor performance status in patients with solid tumors. © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.


Al-Anazi K.A.,King Khalid University | Al-Jasser A.M.,Central Laboratory
Frontiers in Oncology | Year: 2014

Stenotrophomonas maltophilia (S. maltophilia) is a globally emerging Gram-negative bacillus that is widely spread in environment and hospital equipment. Recently, the incidence of infections caused by this organism has increased, particularly in patients with hematological malignancy and in recipients of hematopoietic stem cell transplantation having neutropenia, mucositis, diarrhea, central venous catheters or graft versus host disease and receiving intensive cytotoxic chemotherapy, immunosuppressive therapy or broad-spectrum antibiotics. The spectrum of infections in hematopoietic stem cell transplantation recipients includes: pneumonia, urinary tract and surgical site infection, peritonitis, bacteremia, septic shock and infection of indwelling medical devices. The organism exhibits intrinsic resistance to many classes of antibiotics including carbapenems, aminoglycosides, most of the third generation cephalosporins and other ß-lactams. Despite the increasingly reported drug resistance, trimethoprim-sulfamethoxazole is still the drug of choice However, the organism is still susceptible to: ticarcillin-clavulanic acid, tigecycline, fluoroquinolones, polymyxin-B and rifampicin. Genetic factors play a significant role not only in evolution of drug resistance but also in virulence of the organism. The outcome of patients having S. maltophilia infections can be improved by: using various combinations of novel therapeutic agents and aerosolized aminoglycosides or colistin, prompt administration of in-vitro active antibiotics, removal of possible sources of infection such as infected indwelling intravacular catheters and application of strict infection control measures. © 2014 Al-anazi and Al-jasser.


Minder E.I.,Central Laboratory
Drugs of the Future | Year: 2010

Artificial tanning or induction of skin pigmentation may protect individuals with light-induced skin diseases. The paracrine skin hormone α-melanocyte-stimulating hormone (MSH), acting locally at epidermal melanocytes, is a key player in the tanning response after light-induced stress. The first-in-class synthetic analogue of MSH studied in humans is afamelanotide, which has been shown to activate skin pigmentation or tanning after systemic application. Initially, afamelanotide was administered as a saline solution. Later, a slow-release formulation was used that enabled a marked reduction of the dose and side effects. It has been reported that afamelanotide reduced symptoms in different photodermatoses, including polymorphic light eruption (phase II and III), erythropoietic protoporphyria (phase II and III), phototoxicity of the skin during photodynamic therapy (phase II) and solar urticaria (phase II). However, only a few of these reports have been published. A study aimed at testing the efficacy of afamelanotide in the prevention of actinic keratosis in renal transplant patients is in progress. Reported side effects are minor, including mainly nausea and headache, and notably, no melanoma has been reported. Safety tests showed no toxic effects in mice, rats and minipigs. Copyright © 2010 Prous Science, S.A.U. or its licensors All rights reserved.


Minder E.I.,Central Laboratory
Expert Opinion on Investigational Drugs | Year: 2010

Importance of the field: Afamelanotide, an α-melanocyte stimulating hormone (MSH) agonistic analog is a first-in-class therapeutic. Its application to protoporphyria (PP), a disease associated with absolute sunlight-intolerance is discussed. Areas covered in this review: The genetics and existing therapy of the inherited disease PP comprising both erythropoietic protoporphyria and X-linked dominant protoporphyria. The physiological and pharmacological actions of α-MSH and afamelanotide including receptor-mediated intracellular signaling and effects of receptor polymorphisms. Adverse effects and safety issues. What the reader will gain: The clinical severity and the necessity for an effective therapy for the rare disease PP are illustrated by a short, up-to-date portrait. A condensed description of clinically important aspects of α-MSH signaling, physiological, pharmacological and safety issues of afamelanotide applied to humans and the rational for its potential efficacy in PP are given. The different trials of afamelanotide in PP and their most recent results are discussed. Take home message: Although early, results of the first trials of afamelanotide for PP are promising and the risksafety profile appears favorable today. We expect afamelanotide and analogs thereof to be a prospective therapeutic tool in light-related skin diseases, and in future this drug class might prove effectiveness in other medical conditions. © 2010 Informa UK, Ltd.


Schwarz B.C.,Equine Hospital | Hoven R.V.D.,Equine Hospital | Schwendenwein I.,Central Laboratory
Veterinary Journal | Year: 2012

The myeloperoxidase index (MPXI) was investigated as a diagnostic indicator of systemic inflammation in a retrospective study using data from 859 hospitalised horses. A reference interval of 8.5-10.4 for the MPXI was established. In horses with systemic inflammatory response syndrome (SIRS), the MPXI was significantly lower than in healthy horses, those with localised inflammation and those with sepsis. The MPXI in horses with sepsis was also significantly lower than in healthy animals and those with localised inflammation. Horses in the SIRS group with leucopenia, white blood cell (WBC) count within the reference interval (WRI) or leucocytosis had significantly lower MPXIs than healthy horses, those with localised inflammation and those with sepsis in the same WBC count subgroups. In horses with sepsis and WBC count WRI, the MPXI was significantly lower than in healthy horses or those with localised inflammation. MPXI is a useful complementary tool to identify horses with systemic inflammation, especially if they have WBC counts WRI. © 2010 Elsevier Ltd.


Froom P.,Central Laboratory | Barak M.,Central Laboratory
Clinical Chemistry and Laboratory Medicine | Year: 2012

Background: There are no previous studies reporting the effect of using frozen-thawed plasma on lupus anticoagulant ratios in kits with the combined screen and confirm assay. Methods: In the following study we chose patients with elevated dilute Russel's viper venom test (dRVVT) normalized ratios and compared the test results of fresh to frozen-thawed plasma. Platelet counts ranged from 2 to 7 × 10 3/μ L (10 9/L) after a second centrifugation before freezing. Results: There were 13 out of 14 dRVVT test normalized ratios that decreased after freezing (p < 0.001), leading to the misclassification of six of 14 patients with high values that decreased into the reference interval. Conclusion: The major finding of this study is that testing frozen-thawed plasma with platelet counts < 10,000/μ L (10 9/L) results in a significant decrease in dRVVT ratios. Although there was a consistent decrease in SCT normalized ratios as well, it did not lead to misclassifications. © 2012 by Walter de Gruyter.

Loading Central Laboratory collaborators
Loading Central Laboratory collaborators